Advertisement
Product › Details
APN311 (Apeiron)
Next higher product group | antibody cancer drug | |
Status | 2013-01-16 development p3 existent | |
Organisation | Apeiron Biologics AG | |
Group | Apeiron (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for antibody cancer drug
- [1] MorphoSys AG. (2/5/24). "Press Release: MorphoSys Enters into Business Combination Agreement to Be Acquired by Novartis for € 2.7 Billion Equity Value. Tafasitamab Sold to Incyte". Planegg....
- [2] Catalym GmbH. (1/9/24). "Press Release: Catalym Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists". Mainz....
- [3] Human Immunology Biosciences, Inc. (HI-Bio). (1/4/24). "Press Release: HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases". South San Francisco, CA....
- [4] BioNTech SE. (10/31/23). "Press Release: BioNTech to Present Clinical and Preclinical Data Updates Across Multiple Immuno-Oncology Programs at 2023 SITC Annual Meeting". Mainz....
- [5] BeiGene, Ltd.. (9/19/23). "Press Release: BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody Tevimbra (tislelizumab)". Basel & Beijing & Cambridge, MA....
- [6] Invios GmbH. (9/5/23). "Press Release: Invios Starts Further Clinical Trial of APN401, Novel Cell Therapy Against Solid Cancers, and Secures Major Austrian Grant Funding". Vienna....
- [7] Biotheus Inc.. (7/19/23). "Press Release: Biotheus Announces Strategic Research Collaboration and Worldwide License Agreement with BioNTech". Zhuhai....
- [8] BioNTech SE. (6/29/23). "Press Release: BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC". Mainz & Rockville, MD....
- [9] MorphoSys AG. (5/3/23). "Press Release: MorphoSys AG Reports First Quarter 2023 Financial Results". Planegg....
- [10] BioNTech AG. (3/20/23). "Press Release: BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications". Mainz & Rockville, MD....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top